Acclarent, part of the Johnson & Johnson Medical Devices Companies, has introduced new artificial intelligence (AI)-based ENT navigation technology in the US.

Designed to simplify surgical planning and deliver real-time feedback during ENT navigation procedures, the new software package consists of TruSeg and TruPath for use with the TruDi navigation system.

The new software package is said to leverage a machine learning algorithm to offer image guided preoperative planning and navigation for ENT procedures such as endoscopic sinus surgery.

According to the company, over 30 million adults in the US are diagnosed with sinusitis each year and they suffer from a combination of nasal congestion, facial pain/pressure, decreased sense of smell, and other symptoms that impact the quality of life.

TruDi, which enabled software-guided navigation since its launch in 2018, provides real-time 3D guidance, anatomical mapping, and surgical insights to ENT surgeons to assist throughout procedures.

By using TruSeg, surgeons will be able to apply automatic segmentation to a patient’s anatomical structures based on a preoperative CT scan.

The feature will facilitate the accurate labeling of anatomical structures, including the eyes and brain, to function as radars to alert the surgeon when a navigated surgical device approaches the structure during ENT procedures.

TruPath is used to calculate and present the shortest valid path, which doesn’t cross bone.

Acclarent worldwide president Jeff Hopkins said: “The launch of this AI-powered software for TruDi is a leap forward in the evolution of image-guided ENT and skull base procedures.

“Acclarent continues to reimagine what’s possible with ENT navigation and TruDi continues to benefit patients and the ENT community through consistent accuracy, a simple workflow, and pioneering software functionality.”